Regarding the two stocks he highlights, the author of today’s article declares “these two small-caps are both first movers in healthcare sectors that are ripe for disruption, with massive opportunities over the next decade.”
RAS mutations are the initiating genetic events in many cancers – and have proven to be extremely difficult to target. With its lead compound, however, the oncology company featured in today’s article is “looking to become the backbone of treatment for RAS-driven cancers.
When you think of infrastructure, you likely think of things such as roads, bridges and airports. But the infrastructure plan the Biden Administration just rolled out also includes hundreds of billions of dollars in funding for health care infrastructure.
A clinical-stage company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases is among the three new biotech stocks to watch.
Among the three top biotech stocks to buy right now, as identified by the author of today’s article, is a company that he argues “deserves… Read More »“The Overall Best Biotech Around” – And 2 Other Top Biotech Stock Picks
Is the current downturn a good buying opportunity for biotech stocks? And, if so, which biotech stocks are the most promising picks for aggressive investors?
Two penny stocks that boast “Strong Buy” consensus ratings from the analyst community and massive upside potential.
A clinical-stage biotech company focused on developing tumor-specific immunotherapies to fight multiple cancer types and which is also developing a COVID-19 vaccine that could aid in the battle against variant strains of the virus.
Covid-19 vaccines aren’t the only ones you should be paying attention to” – and they highlight seven “second-tier” biotechs with catalysts beyond COVID-19 vaccines that may be worth considering.
The recent pullback in biotech “offers a chance to get into exciting areas of biotech research like gene editing and oncology at better prices.”